Aethlon Medical (AEMD) Emerging Growth Conference 83 summary

Research and development updates

• Collaborated with UC San Francisco to test device efficacy on long COVID patient plasma, focusing on binding extracellular vesicles and spike protein.

• Preliminary results encouraged submission to the Keystone Conference in August, where findings will be presented.

• Device is an extracorporeal filter compatible with standard hospital machines, targeting extracellular vesicles in cancer and other diseases.

• Recent publication in May highlighted potential applications in oncology, infectious diseases, organ transplantation, and other unmet medical needs.

• Patent applications are underway for new uses related to extracellular vesicle reduction.

Long COVID and market potential

• CDC estimates 6–7% of the US population suffers from long COVID, equating to 44–48 million people.

• No effective therapy or cure exists despite $1 billion in US government spending; current treatments are only symptomatic.

• Preliminary work on long COVID may open opportunities for government grants.

Oncology clinical trials progress

• Oncology trials in India delayed due to regulatory changes, but progress is being made and trial start is expected soon.

• In Australia, three hospitals are participating, with the largest affiliated with the University of Sydney now actively recruiting patients.

• The trial is a safety and dose-escalation study for patients with solid tumors unresponsive to anti-PD-1 therapy.

• First patient treated in January; two more needed to complete the first cohort before advancing to higher dose cohorts.

• University of Sydney lab will analyze immune response and extracellular vesicle reduction as trial milestones are reached.